International Psoriasis Council

Advancing Knowledge. Improving Care.

New Resource Page on Generalized Pustular Psoriasis

BI Resource Page on GPP graphic

Generalized Pustular Psoriasis (GPP) is a rare, lifelong skin disease that may be life-threatening if left untreated. It is characterized by flares that appear suddenly in the form of painful, pus-filled blisters over large body parts. It may be accompanied by more general symptoms, such as fever, headache, extreme tiredness, or a burning sensation on the skin. GPP can be confused with the more common plaque psoriasis, but they are distinct diseases.

Boehringer Ingelheim has created a resource page that includes the latest articles, downloads, and related press releases on GPP to assist with diagnosing and treating this rare disease.

LEARN MORE
[searchwp_search_form engine=blog_search target="/news" var=_blog_search]

Categories

Recent Posts

Six people stand side by side in business attire, smiling at the camera. Behind them, a banner reads IPC International Council 2025 Think Tank Puerto Rico, focused on Psoriasis in Latin America, with colorful designs and sunlight filtering through curtains.

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

VIEW
A large group attends a conference session, with several panelists seated at a table onstage. One attendee stands to ask a question. The IPC (International Psoriasis Council) logo and AAD 2026 appear in the corner.

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

VIEW
A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

VIEW

Also Read
EADV 2025

Focus on Psoriasis: Highlights from the 2025 EADV Congress

At the 2025 EADV Annual Meeting in Paris, experts shared new insights into psoriasis diagnosis, symptoms, and treatment. Highlights include the IPC Symposium, Free Communication sessions, and results from pivotal clinical trials on emerging oral peptides, IL-23 inhibitors, and dose-optimization strategies.

Read More
Tuesday, September 30, 2025

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »
Monday, April 27, 2026

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026